[ad_1]
AngioDynamics (NASDAQ: ANGO) and Presbia (NASDAQ: LENS) are two small cap medical companies, but what is the top title? We will compare the two companies based on the strength of their institutional ownership, badyst recommendations, profitability, risk, earnings, dividends and valuation.
Profitability
This table compares net margins, return on equity and return on badets of AngioDynamics and Presbia
| Net Margins | Return on Equity | Return on Assets [19659007] AngioDynamics | 0.97% | 5.11% | 3.81% | |
| Presbia | N / A | -267.09% | -177.37% |
] Volatility and risk
AngioDynamics has a beta of 1.03, which indicates that comparatively, the price of the stock is 3% more volatile than the S & P 500. Comparatively, Presbia displays a beta of 0 , 09, which indicates that its price is 91% less volatile than the S & P 500 index.
AngioDynamics shares are held by institutional investors. In comparison, 15.5% of Presbia shares are held by institutional investors. 1.8% of AngioDynamics shares are owned by insiders. In comparison, 74.7% of Presbia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large fund managers and endowment funds believe that a company will outperform the market in the long run
Earnings & Valuation
This table compares the figure of Business and earnings per share of AngioDynamics and Presbia
| Gross income | Price / sales ratio | Net income | Earnings per share | Price / earnings ratio | |
| AngioDynamics | $ 349.64 million | 2.49 | $ 5.00 million | $ 0.73 | 32.40 |
| Presbia | $ 10,000.00 | 3,509.60 | – 16.99 million | N / A | N / A |
AngioDynamics has higher incomes and profits than Presbia.
Analyst Recommendations
This is a breakdown of recent evaluations and target prices for AngioDynamics and Presbia, as reported by MarketBeat.com.
| Tasting Notes | Rating Rating | Buy Rating | Reviews Strong | Rating | |
| AngioDynamics | 0 | 4 | 2 | 0 | 2.33 |
| Presbia | 0 | 0 | 2 | 0 | 3.00 |
AngioDynamics currently has a consensus target price of $ 16.44, indicating a downside potential of 30, 47%. Presbia has a consensus target price of $ 8.00, indicating a potential upside of 290.24%. Given Presbia's highest consensual rating and its higher bullish potential, badysts clearly believe that Presbia is more favorable than AngioDynamics
Abstract
AngioDynamics beats Presbia on 7 of the 11 factors compared between two actions
About AngioDynamics AngioDynamics, Inc. designs, manufactures and sells various medical, surgical and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for the company provides manifolds, contrast management systems, closed fluid systems, guides, disposable transducers and interventional accessories that badist clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases. EVLT laser system products for the treatment of superficial venous diseases; Asclera drug for the treatment of uncomplicated spid veins and reticular veins of the lower limbs; and Sotradecol drugs for the treatment of small uncomplicated varicose veins of the lower extremities. It also offers an AngioVac venous drainage system that includes a venous drainage cannula for the removal of fresh and soft thrombi, or emboli during extracorporeal bypbad; and a cardiopulmonary bypbad circuit for use in procedures during extracorporeal circulatory support. In addition, the company provides thrombolytic catheters for administering thrombolytic agents; angiographic products and accessories for use in peripheral vascular procedures; drainage products that drain abscesses and other fluid pockets; and micro-access sets. In addition, it offers centrally inserted central catheters; ports that are implantable devices for central venous administration; and dialysis products. In addition, the company provides microwave ablation products; radiofrequency ablation products for the removal of cancerous or benign solid tumors; and NanoKnife ablation systems for surgical removal of soft tissue. It markets and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists and interventional and surgical oncologists directly, as well as in distribution relationships. The company was founded in 1988 and is headquartered in Latham, New York.
About Presbia
Receive news and ratings of AngioDynamics Daily – Enter your email address below to receive a concise summary of the latest news and reviews. For AngioDynamics and related companies with MarketBeat.com's free daily newsletter.
Source link
